🫀 Semaglutide in Obesity: Reduced Bariatric Surgeries and Postoperative Trajectories

🧪 What was studied — Retrospective analysis (n=515) of bariatric surgery candidates between 2022–2023, comparing those on pre-op semaglutide to non-users. Tracked time to surgery, cancellation, short-term (2, 6 months) weight loss, and reasons for ineligibility.

📈 Key results — Semaglutide users had higher diabetes rates and were less likely to proceed with surgery (P=0.001). Mean time from evaluation to surgery was longer (8.8 vs 7.4 months; P=0.152). 22% of semaglutide users lost enough weight to become ineligible for surgery. Postoperative short-term weight loss was similar between groups.

📍 What this changes in practice — Semaglutide can effectively delay or negate surgery for some obese patients. Care teams should anticipate longer pre-op periods and reassess surgical eligibility periodically. Multidisciplinary counseling regarding long-term weight maintenance after med withdrawal remains advised, as durability vs surgical outcomes is not yet defined.

🔗 Source — PubMed | Full Text

🧾 GLP-1RA Perioperative Management: Pediatric Alert

✅ Do

• Use point-of-care gastric ultrasound for risk assessment if on semaglutide, even with prolonged fasting (>32h solids, >10h liquids).
• Prepare for aspiration risk mitigation (e.g., rapid sequence induction) if full stomach suspected.

⚠️ With caution

• Recognize prolonged gastric emptying can persist for >1 week after last dose, especially during dose titration or in those with GI dysmotility.

🚫 Avoid

• Relying on standard fasting protocols for GLP-1RA users.

🔗 Source — PubMed | Full Text

🧐 Semaglutide vs SGLT2i: Comparative Muscle, Fat, & Glycaemia Effects

🔥 Main in 3 points

• Both oral semaglutide (n=84) and SGLT2i (n=231) reduced HbA1c, body weight, and fat mass similarly at 6 months.
• Only SGLT2i led to significant skeletal muscle mass loss (−0.40 kg, P<0.01) vs semaglutide (−0.10 kg, P=0.74).
• Glycaemic, weight, and fat benefits are comparable, but muscle preservation may be better with semaglutide.

🧪 Context — Retrospective, single-centre, T2DM patients on either therapy ≥6 months. Endpoints: HbA1c, body composition, muscle mass.

📍 Practical significance — Prefer semaglutide for T2D patients at sarcopenia risk or when muscle preservation is a priority. Continue monitoring nutritional status and functional capacity in long-term pharmacotherapy.

🔗 Source — PubMed | Full Text

⚠️ Safety signal: Muscle strength attenuation in older adults on GLP-1RA

🧪 Context — Review of RCTs & observational cohorts examining muscle strength and lean mass in adults on semaglutide, liraglutide, tirzepatide.

📊 Numbers — Short-to-mid-term RCTs: preserved handgrip strength despite lean mass reductions. Longitudinal/retrospective data in older adults: documented handgrip loss & accelerated sarcopenia with extended semaglutide use.

📍 Actions — Monitor muscle strength/function (not just lean mass) in elderly patients on chronic GLP-1 agonists during weight loss. Consider integrating grip strength or physical performance tests at baseline/follow-up, particularly in those at risk for frailty or disability.

🔗 Source — PubMed | Full Text

🫀 Semaglutide in Metabolic Liver Disease: New Guideline Consensus

🔥 Main in 3 points

• Semaglutide is strongly endorsed in new multidisciplinary guidelines for metabolic hepatic steatosis (MetHS), alongside resmetirom, for promoting fibrosis regression.
• Early use of non-invasive fibrosis tools (FIB-4, NFS, HFS, FibroScan®) and robust metabolic intervention (diet/exercise) recommended.
• Guidelines highlight multidisciplinary teams for optimal care and referral to hepatology/endocrinology as indicated.

🧪 Context — Delphi-based Spanish guideline consensus for MetHS/NASH; broad stakeholder input.

📍 Practical significance — Consider semaglutide as a therapeutic option for MetHS patients with fibrosis, as per evolving standards. Optimize team communication for risk stratification and timely escalation.

🔗 Source — PubMed | Full Text